Veru reports strong second-quarter financial results based on record high fc2 prescription revenues

-- first patient to be enrolled this week in phase 3 clinical trial of sabizabulin (veru-111) in high risk hospitalized covid-19 patients-- --new drug application accepted for review by fda for proprietary tadfin daily oral dosing combination for bph; pdufa date december 2021--
VERU Ratings Summary
VERU Quant Ranking